Quick Answer
ABVC BIOPHARMA, INC. reported Gross Profit of $508.8 thousand for fiscal year 2024.
ABVC BIOPHARMA, INC. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $508.8K | +440.1% |
| 2023 | -$149.6K | -121.9% |
| 2022 | $683.4K | +94.9% |
| 2021 | $350.7K | -24.5% |
| 2020 | $464.3K | -31.9% |
| 2019 | $681.6K | +482.2% |
| 2018 | -$178.3K | -557162.5% |
| 2016 | -$32.00 | -101.1% |
| 2015 | $2.8K | — |
| 2014 | $0.00 | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $796.0K | +104.6% | +104.6% |
| September 30, 2024 | $389.0K | +2933.1% | +232.6% |
| June 30, 2024 | $117.0K | +274.9% | +12502.6% |
| March 31, 2024 | $928.00 | -98.6% | +106.8% |
| September 30, 2023 | -$13.7K | -143.5% | +79.5% |
| June 30, 2023 | -$66.9K | -122.0% | -198.3% |
| March 31, 2023 | $68.0K | +186.3% | +115.8% |
| September 30, 2022 | $31.5K | -68.0% | -89.6% |
- ABVC BIOPHARMA, INC. showed an increase of +440.1% in Gross Profit compared to the prior fiscal year.
- The most recent figure is from ABVC BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: